nm23-H1 gene driven by hTERT promoter induces inhibition of invasive phenotype and metastasis of lung cancer xenograft in mice

Thoracic Cancer

Volumn 4, Issue 1, 2013, Pages 41-52

  Fan, Yu ^a,b   Yao, Yibing ^b   Li, Lu ^a   Wu, Zhihao ^b   Xu, Feng ^a   Hou, Mei ^a   Wu, Heng ^b   Shen, Yali ^a   Wan, Haisu ^b   Zhou, Qinghua ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Gene therapy; HTERT; Metastasis; Nm23 H1; Targeted gene expression

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; NUCLEOSIDE DIPHOSPHATE KINASE A; TELOMERASE REVERSE TRANSCRIPTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASSAY; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DISTANT METASTASIS; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NEOPLASM; NONHUMAN; NONVIRAL GENE THERAPY; PHENOTYPE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; TUMOR XENOGRAFT;

EID: 84873285095     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/j.1759-7714.2012.00140.x     Document Type: Article

References (55)

1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011; 32: 605-44.
2. Agarwal M, Brahmanday G, Chmielewski GW, Welsh RJ, Ravikrishnan KP. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer 2010; 68: 398-402.
3. Gudbjartsson T, Smáradottir A, Skúladóttir H etal. [Lung cancer-review]. Laeknabladid 2008; 94: 297-311. (In Icelandic.).
4. Ohe Y. Chemoradiotherapy for lung cancer: current status and perspectives. Int J Clin Oncol 2004; 9: 435-43.
5. Steeg PS, Bevilacqua G, Kopper L etal. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80: 200-4.
6. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003; 3: 55-63.
7. Tee YT, Chen GD, Lin LY, Ko JL, Wang PH. Nm23-H1: a metastasis-associated gene. Taiwan J Obstet Gynecol 2006; 45: 107-13.
8. Novak M, Jarrett SG, McCorkle JR, Mellon I, Kaetzel DM. Multiple mechanisms underlie metastasis suppressor function of NM23-H1 in melanoma. Naunyn Schmiedebergs Arch Pharmacol 2011; 384: 433-8.
9. Arai T, Yamashita T, Urano T etal. Preferential reduction of nm23-H1 gene product in metastatic tissues from papillary and follicular carcinomas of the thyroid. Mod Pathol 1995; 8: 252-6.
10. Luo W, Matsuo K, Nagayama Y etal. Immunohistochemical analysis of expression of nm23-H1/nucleoside diphosphate kinase in human thyroid carcinomas: lack of correlation between its expression and lymph node metastasis. Thyroid 1993; 3: 105-9.
11. Liu L, Qin Y, Zhou Qetal [Northern blot analysis of nm23 gene expression in human lung cancer. Chin J Oncol 1998; 20: 342-4. (In Chinese.).
12. Chen XF, Zhou QH, Zhang SF etal. A study on the relationship between nm23-H1 gene expression and the prognosis in patients with non-small cell lung cancer. J Chin Exp Surg 2002; 19: 40-42.
13. Chen J, Zhou Q, Qin Y, Sun Z, Sun Z, Liu L. A study on the allelic deletion of nm23 genes in human lung cancer. Chin J Lung Cancer 2000; 3: 8-13.
14. Che GW, Chen J, Liu LX etal. Transfection of nm23-H1 increased expression of beta-Catenin, E-Cadherin and TIMP-1 and decreased the expression of MMP-2, CD44v6 and VEGF and inhibited the metastatic potential of human non-small cell lung cancer cell line L9981. Neoplasma 2006; 53: 530-7.
15. Park YP, Kim KD, Kang SH etal. Human telomerase reverse transcriptase (hTERT): a target molecule for the treatment of cisplatin-resistant tumors. Korean J Lab Med 2008; 28: 430-7.
16. Zhou QH, Wang YP, Che GW etal. [Establishment and their biological characteristics of clonal cell subpopulations (NL9980 and L9981) from a human lung large cell carcinoma cell line (WCQH-9801)]. Chin J Lung Cancer 2003; 6: 464-8. (In Chinese.).
17. Takakura M, Kyo S, Kanaya T etal. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999; 59: 551-7.
18. Zhou QH, Yang XQ, Zhu DX etal. Double mutant P96S/S120G of Nm23-H1 abrogates its NDPK activity and motility-suppressive ability. Biochem Biophys Res Commun 2007; 356: 348-53.
19. Salerno M, Palmieri D, Bouadis A, Halverson D, Steeg PS. Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells. Mol Cell Biol 2005; 25: 1379-88.
20. Du J, Hannon GJ. The centrosomal kinase Aurora-A/STK15 interacts with a putative tumor suppressor NM23-H1. Nucleic Acids Res 2002; 30: 5465-75.
21. Roymans D, Willems R, Vissenberg K etal. Nucleoside diphosphate kinase beta (Nm23-R1/NDPKbeta) is associated with intermediate filaments and becomes upregulated upon cAMP-induced differentiation of rat C6 glioma. Exp Cell Res 2000; 261: 127-38.
22. Ma W, Chen J, Xue X etal. Alteration in gene expression profile and biological behavior in human lung cancer cell line NL9980 by nm23-H1 gene silencing. Biochem Biophys Res Commun 2008; 371: 425-30.
23. Li Y, Zhou QH, Sun ZL etal. [Experimental study on molecular mechanism of nm23-HI gene transfection reversing the malignant phenotype of human high-metastatic large cell lung cancer cell line. Chin J Lung Cancer 2006; 9: 307-11. (In Chinese.).
24. Li DB, Zhou QH, Wang YP etal. [Experimental study of effects of nm23-HI gene transfection on the change of PKA activity in human high-metastasis large cell lung cancer cell line L9981. Chin J Lung Cancer 2004; 7: 91-4. (In Chinese).
25. Fu JK, Zhou QH, Zhu W etal. [Targeting blockage of Wnt signal transduction pathway of nm23-H1 gene transfection in human high-metastatic large cell lung cancer cell line L9981. Chin J Lung Cancer 2004; 7: 294-7. (In Chinese.).
26. Ma L, Zhou QH, Zhu W etal. [Effects of nm23-H1 point mutation on activity of GSK-3β in human high-metastatic large cell lung cancer cell line L9981. Chin J Lung Cancer 2006; 9: 30-34. (In Chinese.).
27. Nie Q, Zhou QH, Zhu W etal. [nm23-H1 gene inhibits lung cancer cell invasion through down-regulation of PKC signal pathway. Chin J Oncol 2006; 28: 334-6. (In Chinese.).
28. Murakami M, Meneses PI, Knight JS etal. Nm23-H1 modulates the activity of the guanine exchange factor Dbl-1. Int J Cancer 2008; 123: 500-10.
29. Zheng HX, Zhou QH, Sun ZL etal. [Regulation of nm232H1 transfection on expression of integrins in human high-metastasis large cell lung cancer cell line L9981. Chin J Lung Cancer 2004; 7: 108-11. (In Chinese.).
30. Suzuki E, Ota T, Tsukuda K etal. nm23-H1 reduces in vitro cell migration and the liver metastatic potential of colon cancer cells by regulating myosin light chain phosphorylation. Int J Cancer 2004; 108: 207-11.
31. Otsuki Y, Tanaka M, Yoshii S, Kawazoe N, Nakaya K, Sugimura H. Tumor metastasis suppressor nm23H1 regulates Rac1 GTPase by interaction with Tiam1. Proc Natl Acad Sci U S A 2001; 98: 4385-90.
32. Onimaru M, Ohuchida K, Mizumoto K etal. hTERT-promoter-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells. Cancer Sci 2010; 101: 735-42.
33. Wang W, Jin B, Li W etal. Targeted antitumor effect induced by hTERT promoter mediated ODC antisense adenovirus. Mol Biol Rep 2010; 37: 3239-47.
34. Xie X, Hsu JL, Choi MG etal. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther 2009; 8: 2375-82.
35. Fujiwara T, Tanaka N. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Uirusu 2008; 58: 11-18.
36. Tang XJ, Wang YP, Zhou QH etal. Cloning of human telomerase catalytic subunit gene promoter and studying on its specific transcriptional activities in human lung cancer cell. Chin J Lung Cancer 2004; 7: 475-9. (In Chinese.).
37. Yang LF, Zhao Y, Zeng L, Gong JP, Cao Y. hTERT/re-caspase-3 system induce apoptosis in hTERT-positive cancer cells. Cancer Biol Ther 2006; 5: 1546-53.
38. Komata T, Kondo Y, Kanzawa T etal. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 2001; 61: 5796-802.
39. Koga S, Hirohata S, Kondo Y etal. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res 2001; 21: 1937-43.
40. Abdul-Ghani R, Ohana P, Matouk I etal. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2000; 2: 539-44.
41. Dudognon C, Pendino F, Hillion J, Saumet A, Lanotte M, Ségal-Bendirdjian E. Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance. Oncogene 2004; 23: 7469-74.
42. Li JT, Bian K, Zhang AL etal. Targeting different types of human meningioma and glioma cells using a novel adenoviral vector expressing GFP-TRAIL fusion protein from hTERT promoter. Cancer Cell Int 2011; 11: 35-48.
43. Toyota H, Kondo S, Kyo S, Mizuguchi J. Enforced expression of a truncated form of Bax-alpha (tBax) driven by human telomerase reverse transcriptase (hTERT) promoter sensitizes tumor cells to chemotherapeutic agents or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Anticancer Res 2006; 26: 99-105.
44. Wang YP, Tang XJ, Zhou QH, Che GW, Chen XH, Zhu DX. [An experimental study on targeting suicide gene therapy for lung cancer with HSV-TK driven by hTERT promoter]. Sichuan Da Xue Xue Bao Yi Xue Ban 2008; 39: 701-5. (In Chinese.).
45. Liu J, Zou WG, Lang MF etal. Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter. Int J Oncol 2002; 21: 661-6.
46. Takeda T, Inaba H, Yamazaki M etal. Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter. J Clin Endocrinol Metab 2003; 88: 3531-8.
47. Song JS, Kim HP. Adenovirus-mediated HSV-TK gene therapy using the human telomerase promoter induced apoptosis of small cell lung cancer cell line. Oncol Rep 2004; 12: 443-7.
48. Li F, Tan XH, Peng XJ, Cai HB, Hu DR. [Cloning of human telomerase reverse transcriptase promoter for targeted cancer therapy]. Di Yi Jun Yi Da Xue Xue Bao 2005; 25: 207-11. (In Chinese.).
49. Yu B, Zhang Y, Zhan Y etal. Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects. Oncol Rep 2011; 26: 255-64.
50. Takeuchi H, Kanzawa T, Kondo Y etal. Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells. Int J Oncol 2004; 25: 57-63.
51. Jacob D, Davis JJ, Zhang L, Zhu H, Teraishi F, Fang B. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther 2005; 12: 109-15.
52. Lin T, Zhang L, Davis J etal. Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther 2003; 8: 441-8.
53. Sawada T, Yamada O, Yoshimura N, Hatori K, Fuchinoue S, Teraoka S. Xenoantigen, an alphaGal epitope-expression construct driven by the hTERT-promoter, specifically kills human pancreatic cancer cell line. Cancer Cell Int 2002; 2: 14-20.
54. Nakamura M, Kyo S, Kanaya T etal. hTERT-promoter-based tumor-specific expression of MCP-1 effectively sensitizes cervical cancer cells to a low dose of cisplatin. Cancer Gene Ther 2004; 11: 1-7.
55. Song JS. Activity of the human telomerase catalytic subunit (hTERT) gene promoter could be increased by the SV40 enhancer. Biosci Biotechnol Biochem 2004; 68: 1634-9.